NYHA Class IV Approval: In August 2024, scPharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted approval for FUROSCIX, expanding the indication to include New York Heart ...
An unknown number of troops are suffering from mysterious neurological issues that researchers suspect could be linked to blasts caused by their own weapons.